Abstract
Cancer genome sequencing is useful for diagnosis and personalized treatment. Analysis of the sequencing data involves integration of computation, statistics and system biology methods. The amalgam of such methods which help study interaction of cancer cells with immune system, harnessing immune system for cancer therapy or its prevention through vaccines has led to the foundation of cancer immunomics. It is, therefore, a combinatorial science which merges diverse techniques from genomics and proteomics for diagnosis and drug design/treatment. There has been a gradual increase in establishment of cancer immune focused start-ups, research facilities and pharma giants working on state-of-the-art methods for improving diagnostics, treatment and prevention or minimizing side effects, applying immunomics. However, we are still far away from making precise, quick and reliable diagnostic and treatment predictions. We need decision support systems to facilitate diagnosis, tumor evaluation prediction and assessment of individual profile for making personalized therapy a reality. The future is centered not only on data management but wise decision aided by artificially intelligent algorithms. In this review, we provide an overall picture and focus on immune biomarkers and relevant softwares that aid in diagnostics and analysis of cancer.
Keywords: Immunomics, cancer informatics, immunoinformatics, diagnostics, biomarkers, personalized therapy.
Current Pharmaceutical Design
Title:Cancer Immunomics in the Age of Information: Role in Diagnostics and Beyond
Volume: 24 Issue: 32
Author(s): Zarrin Basharat, Azra Yasmin*Nosheen Masood
Affiliation:
- Microbiology & Biotechnology Research Lab, Department of Environmental Sciences, Fatima Jinnah Women University-46000, Rawalpindi,Pakistan
Keywords: Immunomics, cancer informatics, immunoinformatics, diagnostics, biomarkers, personalized therapy.
Abstract: Cancer genome sequencing is useful for diagnosis and personalized treatment. Analysis of the sequencing data involves integration of computation, statistics and system biology methods. The amalgam of such methods which help study interaction of cancer cells with immune system, harnessing immune system for cancer therapy or its prevention through vaccines has led to the foundation of cancer immunomics. It is, therefore, a combinatorial science which merges diverse techniques from genomics and proteomics for diagnosis and drug design/treatment. There has been a gradual increase in establishment of cancer immune focused start-ups, research facilities and pharma giants working on state-of-the-art methods for improving diagnostics, treatment and prevention or minimizing side effects, applying immunomics. However, we are still far away from making precise, quick and reliable diagnostic and treatment predictions. We need decision support systems to facilitate diagnosis, tumor evaluation prediction and assessment of individual profile for making personalized therapy a reality. The future is centered not only on data management but wise decision aided by artificially intelligent algorithms. In this review, we provide an overall picture and focus on immune biomarkers and relevant softwares that aid in diagnostics and analysis of cancer.
Export Options
About this article
Cite this article as:
Basharat Zarrin , Yasmin Azra *, Masood Nosheen, Cancer Immunomics in the Age of Information: Role in Diagnostics and Beyond, Current Pharmaceutical Design 2018; 24 (32) . https://dx.doi.org/10.2174/1381612824666181106091903
DOI https://dx.doi.org/10.2174/1381612824666181106091903 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sulfotransferase 1A1 as a Biomarker for Susceptibility to Carcinogenesis: From Molecular Genetics to the Role of Dietary Flavonoids
Current Drug Metabolism CYR61 Confers the Sensitivity to Aromatase Inhibitor Letrozole in ER Positive Breast Carcinoma
Current Cancer Drug Targets Therapeutic Potential of Nucleic Acid-Based Drugs in Coronary Hyper- Proliferative Vascular Diseases
Current Medicinal Chemistry Histone Deacetylase Inhibitors in Tumor Immunotherapy
Current Medicinal Chemistry Unveiling the Role of Nuclear Transport in Epithelial-to-Mesenchymal Transition
Current Cancer Drug Targets Cellular and Molecular Effects of Macrolides on Leukocyte Function
Current Pharmaceutical Design CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy
Current Topics in Medicinal Chemistry Editorial [Hot topic: Special Edition Myeloproliferative Neoplasia – Disease Pathogenesis and Treatment Options (Guest Editors: D. Wolf and H. Rumpold)]
Current Cancer Drug Targets The Emerging Roles of RASSF5 in Human Malignancy
Anti-Cancer Agents in Medicinal Chemistry Structural Effects of TiO2 Nanoparticles and Doxorubicin on DNA and their Antiproliferative Roles in T47D and MCF7 Cells
Anti-Cancer Agents in Medicinal Chemistry Azoles as Effective Antifungal Agents: Trends, Scope and Relevance
The Natural Products Journal Potential Uses of MicroRNA in Lung Cancer Diagnosis, Prognosis, and Therapy
Current Cancer Drug Targets Mucosal Vaccines: Where Do We Stand?
Current Topics in Medicinal Chemistry Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issues
Current Pharmaceutical Design Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes
Current Topics in Medicinal Chemistry Why Some Messages Speak Better: Child Immunization in the News and on the Internet
Current Drug Safety Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease
Current Topics in Medicinal Chemistry Bioavailability Enhancement Strategies: Basics, Formulation Approaches and Regulatory Considerations
Current Drug Delivery